Registration of Novatim as a company.

Novatim was officailly recognized as a Technology-based Small and Medium-sized Enterprise.

Project of Phase I/II Clinical Research on a Novel IL2 Fusion Protein Targeting PD-1 for the Treatment of Advanced Malignant Tumors: shortlisted for the Top Soldier（尖兵）and Leading Wild Goose（领雁） R&D Plan of Zhejiang Province, 2023.

Pre-IND application of a dual target CAR-T solution for refractory recurrent multiple myeloma, by Shanghai Tinova Immune Therapeutics Co., Ltd., a fully-owned subsidiary of Novatim.

Completion of the first round of financing with about ￥500 million by Novatim.

Approval of KY-0118 injection, the first domestic mutant IL-2 fusion protein targeting PD-1, independently developed by Novatim from scratch, by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for clinical trials.

Novatim acquired a new headquarter in Anji, Zhejiang, in preparation of future IPO  and renamed as Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) officially started the process of examining KY-0118 injection as a new candidate drug for the treatment of mid-to-late stage solid tumors.

Lauched Phase I infrastructure construction of Novatim headquarter in Anji, Zhejiang province, with clinical and GMP laboratories covering over 50,000 square meters.

Novatim started filing for IPO on the NASDAQ.